Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 + Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer
NCT05430906Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Nov 2022
- Primary completion
- Dec 2023
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in ovarian cancer, sponsored by Hunan Cancer Hospital. Started Nov 2022; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05430906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05430906.